Progestin as an Inhibitor of Premature Ovulation through LH Suppression in IVF

Jump To References Section

Authors

  • Joydeep Das
     Department of Zoology, Dinabandhu Andrews College, Kolkata - 700084, West Bengal ,IN
  • Banani Bindhani
     Department of Zoology, Dinabandhu Andrews College, Kolkata - 700084, West Bengal ,IN
  • Sneha Maity
     Department of Zoology, Dinabandhu Andrews College, Kolkata - 700084, West Bengal ,IN

DOI:

https://doi.org/10.18311/jer/2022/30705

Keywords:

GnRH Analogue, IVF, Progestin, PPOS

Abstract

Progestin is a synthetic form of progesterone hormone. Progestin is used as a contraceptive pill. Progestin can suppress
endogenous Luteinizing Hormone (LH) secretion from the pituitary. Premature ovulation in Assisted Reproductive
Technology (ART)can be prevented by taking progestin. Progestin–Primed Ovarian Stimulation (PPOS) is now widely used
for the treatment of infertility through IVF. Progestin pills are more effective than GnRH analogue for patients. Progestins
are an excellent alternative to antagonists. PPOS is slightly more advantageous than the Controlled Ovarian Stimulation
(COS) protocol. Progesterone regulates follicular growth through PI3K/AKT and MAPK signaling pathway.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Downloads

Published

2022-11-25

How to Cite

Das, J., Bindhani, B., & Maity, S. (2022). Progestin as an Inhibitor of Premature Ovulation through LH Suppression in IVF. Journal of Endocrinology and Reproduction, 26(3), 153–161. https://doi.org/10.18311/jer/2022/30705

Issue

Volume 26, Issue 3, September 2022

Section

Review Article
Crossref
Scopus
Google Scholar
Europe PMC

 

References

Vander Borght M, Wyns C. Fertility and infertility: Definition and epidemiology. Clinical biochemistry. 2018; 62:2-10. https://doi. org/10.1016/j.clinbiochem.2018.03.012 PMid:29555319

Diamond MP, Kruger M, Santoro N, Zhang H, Casson P, Schlaff W, Coutifaris C, Brzyski R, Christman G, Carr BR, McGovern PG. Endometrial shedding effect on conception and live birth in women with polycystic ovary syndrome. Obstetrics and Gynecology. 2012; 119(5):902-8. https://doi.org/10.1097/AOG.0b013e31824da35c PMid:22525900 PMCid:PMC4007263

La Marca A, Capuzzo M. Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: the beginning of a new era? Reproductive Biomedicine Online. 2019; 39(2):321-31. https://doi.org/10.1016/j.rbmo.2019.03.212 PMid:31138494

Messinis IE, Messini CI, Dafopoulos K. Novel aspects of the endocrinology of the menstrual cycle. Reproductive biomedicine online. 2014; 28(6):714-22. https://doi.org/10.1016/j.rbmo.2014.02.003 PMid:24745832

Mehta RH, Anand Kumar TC. Can GnRH agonists act directly on the ovary and contribute to cyst formation? Human Reproduction. 2000; 15(3):505-7. https://doi.org/10.1093/humrep/15.3.505 PMid:10686187

Zhu X, Zhang X, Fu Y. Utrogestan as an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Medicine. 2015; 94(21). https://doi.org/10.1097/ MD.0000000000000909 PMid:26020402 PMCid:PMC4616424

Serour GI, Aboulghar M, Mansour R, Sattar MA, Amin Y, Aboulghar H. Complications of medically assisted conception in 3,500 cycles. Fertility and Sterility. 1998; 70(4):638-42. https://doi.org/10.1016/S0015-0282(98)00250-7

Talaulikar VS, Arulkumaran S. Maternal, perinatal and long-term outcomes after assisted reproductive techniques (ART): implications for clinical practice. European Journal of Obstetrics and Gynecology and Reproductive Biology. 2013; 170(1):13-9. https://doi.org/10.1016/j.ejogrb.2013.04.014 PMid:23759305

Wei D, Shi Y, Li J, Wang Z, Zhang L, Sun Y, Zhou H, Xu Y, Wu C, Liu L, Wu Q. Effect of pretreatment with oral contraceptives and progestins on IVF outcomes in women with polycystic ovary syndrome. Human Reproduction. 2017; 32(2):354-61. https://doi. org/10.1093/humrep/dew325 PMid:27999118 PMCid:PMC5870982

Wang Y, Chen Q, Wang N, Chen H, Lyu Q, Kuang Y. Controlled ovarian stimulation using medroxyprogesterone acetate and hMG in patients with polycystic ovary syndrome treated for IVF: A double-blind randomized crossover clinical trial. Medicine. 2016; 95(9). https://doi.org/10.1097/MD.0000000000002939 PMid:26945402 PMCid:PMC4782886

Xiao ZN, Peng JL, Yang J, Xu WM. Flexible GnRH antagonist protocol versus Progestin-Primed Ovarian Stimulation (PPOS) protocol in patients with polycystic ovary syndrome: Comparison of clinical outcomes and ovarian response. Current Medical Science. 2019; 39(3):431-6. https://doi.org/10.1007/s11596-019-2055-x PMid:31209815

Garcia-Velasco JA, Fatemi HM. To pill or not to pill in GnRH antagonist cycles: that is the question! Reproductive BioMedicine Online. 2015; 30(1):39-42. https://doi.org/10.1016/j.rbmo.2014.09.010 PMid:25447926

Ganesh A, Chakravorty N, Mukherjee R, Goswami S, Chaudhury K, Chakravarty B. Comparison of oral dydrogestrone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: A randomized clinical study. Fertility and Sterility. 2011; 95(6):1961-5. https://doi.org/10.1016/j.fertnstert.2011.01.148 PMid:21333984

Germond M, Capelli P, Bruno G, Vesnaver S, Senn A, Rouge N, Biollaz J. Comparison of the efficacy and safety of two formulations of micronized progesterone (Ellios™ and Utrogestan™) used as luteal phase support after in vitro fertilization. Fertility and Sterility. 2002; 77(2):313-7. https://doi.org/10.1016/S0015-0282(01)02979-X

Ata B, Capuzzo M, Turkgeldi E, Yildiz S, La Marca A. Progestins for pituitary suppression during ovarian stimulation for ART: A comprehensive and systematic review including meta-analyses. Human Reproduction Update. 2021; 27(1):48-66. https://doi. org/10.1093/humupd/dmaa040 PMid:33016316

Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH. Classification and pharmacology of progestins. Maturitas. 46: S7-S16. https://doi.org/10.1016/j.maturitas.2003.09.014 PMid:14670641

Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q, Ai A, Shoham Z. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertility and Sterility. 2015; 104(1):62-70. https://doi.org/10.1016/j.fertnstert.2015.03.022 PMid:25956370

Evans NP, Richter TA, Skinner DC, Robinson JE. Neuroendocrine mechanisms underlying the effects of progesterone on the oestradiol-induced GnRH/LH surge. Reproduction (Cambridge, England) Supplement. 2002; 59:57-66.

Heikinheimo O, Gordon K, Williams RF, Hodgen GD. Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions. Contraception. 1996; 53(1):55-64. https://doi.org/10.1016/0010- 7824(95)00255-3

Gordon A, Garrido-Gracia JC, Aguilar R, Sánchez-Criado JE. Understanding the regulation of pituitary progesterone receptor expression and phosphorylation. Reproduction. 2015; 149(6):615-23. https://doi.org/10.1530/REP-14-0592 PMid:25926689

Chen Q, Chai W, Wang Y, Cai R, Zhang S, Lu X, Zeng X, Sun L, Kuang Y. Progestin vs. gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment: a randomized controlled trial. Frontiers in Endocrinology. 2019; 10:796. https://doi.org/10.3389/fendo.2019.00796 PMid:31824419 PMCid:PMC6882854

Inaudi P, Barra V, Vellucci FL, Regini C, Luisi S. GnRH antagonist does not prevent premature luteinization and ovulation in stimulated cycles with gonadotropins for IVF: Two case reports. Gynecological Endocrinology. 2018; 34(3):189-91. https://doi. org/10.1080/09513590.2017.1380183 PMid:28942696

Attardi B, Scott R, Pfaff D, Fink G. Facilitation or Inhibition of the Oestradiol‐Induced Gonadotrophin Surge in the Immature Female Rat by Progesterone: Effects on Pituitary Responsiveness to Gonadotrophin‐Releasing Hormone (GnRH), GnRH Self‐Priming and Pituitary mRNAs for the Progesterone Receptor A and B Isoforms. Journal of Neuroendocrinology. 2007; 19(12):988-1000. https://doi.org/10.1111/j.1365-2826.2007.01613.x PMid:18001329

Polexa A, Yildiz S, Ata B. The effectiveness of progestins for pituitary suppression during ovarian stimulation in IVF procedures. Acta Medica Transilvanica. 2021; 26(1). https://doi.org/10.2478/amtsb-2020-0016

Chen H, qin Chen Z, Ng EH, Yao D. Comparison of the Cumulative Live Birth Rates After One ART Cycle Including All Subsequent Frozen-thaw Cycles in Women Undergoing IVF Using Progestin Primed Ovarian Stimulation Versus Long GnRH Agonist Protocol. Research Square 2021. https://doi.org/10.22541/au.162654880.07207801/v1

Zolfaroli I, Ferriol GA, Mora JJ, Cano A. Impact of progestin ovarian stimulation on newborn outcomes: a meta-analysis. Journal of assisted reproduction and genetics. 2020; 37(5):1203-12. https://doi.org/10.1007/s10815-020-01755-0 PMid:32215824 PMCid:PMC7244671

Durdağ GD, Bektaş G, Türkyılmaz E, et al. The efficacy of dydrogesteroneuse to suppress premature luteinizing hormone surge on cycle outcomes in controlled ovarian stimulation. Journal of the Turkish German Gynecological Association. 2021; 22(4):293. https://doi.org/10.4274/jtgga.galenos.2020.2020.0110 PMid:33389927 PMCid:PMC8666995

Huang J, Xie Q, Lin J, Lu X, Zhu J, Gao H, Cai R, Kuang Y. Progestin-primed ovarian stimulation with dydrogesterone versus medroxyprogesterone acetate in women with Polycystic Ovarian Syndrome for in vitro fertilization: a retrospective cohort study. Drug Design, Development and Therapy. 2019; 13:4461. https://doi.org/10.2147/DDDT.S230129 PMid:32099323 PMCid:PMC6997218

Beguería R, García D, Vassena R, Rodríguez A. Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Human Reproduction. 2019; 34(5):872-80. https://doi.org/10.1093/humrep/dez034 PMid:30927417

Long H, Yu W, Yu S, et al. Progesterone affects clinic oocyte yields by coordinating with follicle stimulating hormone via PI3K/AKT and MAPK pathways. Journal of Advanced Research. 2021; 33:189-99. https://doi.org/10.1016/j.jare.2021.02.008 PMid:34603789 PMCid:PMC8463924

Hunzicker-Dunn M, Maizels ET. FSH signaling pathways in immature granulosa cells that regulate target gene expression: branching out from protein kinase A. Cellular Signalling. 2006; 18(9):1351-9. https://doi.org/10.1016/j.cellsig.2006.02.011 PMid:16616457 PMCid:PMC1564187

Robker RL, Richards JS. Hormone-induced proliferation and differentiation of granulosa cells: a coordinated balance of the cell cycle regulators cyclin D2 and p27Kip1. Molecular Endocrinology. 1998; 12(7):924-40. https://doi.org/10.1210/mend.12.7.0138 PMid:9658398

Burgering BM, Kops GJ. Cell cycle and death control: long live Forkheads. Trends in biochemical sciences. 2002; 27(7):352-60. https://doi.org/10.1016/S0968-0004(02)02113-8

Burgering BM, Medema RH. Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty. Journal of leukocyte biology. 2003; 73(6):689-701. https://doi.org/10.1189/jlb.1202629 PMid:12773501

Huang H, Itaya Y, Samejima K, et al. Usefulness of random-start progestin-primed ovarian stimulation for fertility preservation. Journal of Ovarian Research. 2022; 15(1):1-6. https://doi.org/10.1186/s13048-021-00935-5n PMid:34983605 PMCid:PMC8725433

Kasum M, von Wolff M, Franulic D, et al. Fertility preservation options in breast cancer patients. Gynecological Endocrinology. 2015; 31(11):846-51.

Yu S, Long H, Chang HY, et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVFA randomized controlled trial including 516 first IVF/ICSI cycles. Human Reproduction. 2018; 33(2):229-37. https://doi. org/10.1093/humrep/dex367 PMid:29300975